

## Virtual Participants Programme

Time: CEST - Central European Summer Time

**Monday, 30 May 2022**

### Young Scientist Retreat Pancreatic Cancer Research Centers Germany

<b>10:00–10:05 am</b>	<b>Welcome and introduction</b> Roland M. Schmid (Spokesperson Collaborative Research Centre CRC1321)
<b>10:00 am–1:00pm</b> <i>Session chairs</i>	<b>Young Scientist Session</b> <i>Laura Eichelberger (University Hospital rechts der Isar, Technical University of Munich, DE)</i> <i>Laura Urbach (University Medical Center Göttingen, DE)</i> <i>Marion Meixner (Philipps-University Marburg, DE)</i>
10:05–10:25 am	Vanessa Zimmer (Clinical Research Unit 325 Philipps-University Marburg, DE) Role of myeloid cell subpopulations for IL-18-mediated T cell exhaustion in a murine pancreatic cancer model
10:25–10:45 am	Lena Cook (Clinical Research Unit 325, Philipps-University Marburg, DE) ADAM8-Dependent Extracellular Signaling in the Tumor Microenvironment Involves Regulated Release of Lipocalin 2 and MMP-9
10:45–11:05 am	Tamara Isermann (Clinical Research Unit 5002, University Medical Center Göttingen, DE) Gain-of-Function p53 mutant specificity predicts invasion in colorectal and pancreatic cancer
11:05–11:25 am	Laura Roth (Research Training Group 2751 InCuPanC, University Halle, DE) The influence of adipocytes on early PDAC carcinogenesis
11:25–11:40 am	<b>Break</b>
11:40–12:00 am	Karly Conrads (Clinical Research Unit 5002, University Medical Center Göttingen, DE) Molecular subtyping in PDAC translational models
12:00–12:20 am	Andrea Terrasi (CRC1321, Ludwig-Maximilians-University Munich, DE) Foxj1 is a novel master regulator of activated PI3k pathway pancreatic cancer
12:20–12:40 am	Aristeidis Papargyriou (CRC1321, University Hospital rechts der Isar, Technical University of Munich, DE) Modeling pancreatic cancer morphogenesis by self-organized branching organoids
12:40 am–1:00 pm	Nico Hesselbarth (Research Training Group 2751 InCuPanC, University Halle, DE) t.b.a.
<b>1:00–3:00 pm</b>	<b>Break</b>

### International Conference Pancreatic Cancer Research Centers Germany

<b>3:00–3:15 pm</b>	<b>Welcome and introduction</b> Roland M. Schmid (Spokesperson Collaborative Research Centre CRC1321)
<b>3:15–6:15 pm</b> <i>Session chairs</i>	<b>Session 1   Out-of-the-box</b> <i>Markus Lerch (Hospital of the Ludwig-Maximilians-University Munich, DE)</i> <i>Nisar Malek (University Hospital of Tübingen, DE)</i>
3:15–3:45 pm	René Bernards (The Netherlands Cancer Institute, Amsterdam, NL) Innovative combination therapies for KRAS mutant cancers
3:45–4:15 pm	Daniel Dauch (University Hospital Tübingen, DE) Efficient targeting of p38alpha in gastrointestinal cancer
4:15–4:45 pm	<b>Break</b>
4:45–5:15 pm	Christian Reinhardt (Clinic for Hematology, University Hospital Essen, DE) Targeting the DNA damage response for personalized cancer therapy
5:15–5:45 pm	Jos Jonkers (The Netherlands Cancer Institute, Amsterdam, NL) Understanding and overcoming PARP inhibitor resistance
5:45–6:15 pm	Laura Soucek (Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES) A clinically viable MYC inhibitor for cancer treatment
6:15–6:30 pm	<b>Break</b>
<b>6:30–7:10 pm</b> <i>Session chair</i>	<b>Keynote lecture</b> <i>Roland M. Schmid (University Hospital rechts der Isar, Technical University of Munich, DE)</i> <i>Martin Eilers (Biocenter of the University of Würzburg, DE)</i> Understanding and targeting MYC function in pancreatic cancer

**Tuesday, 31 May 2022**

<b>9:00–12:15 am</b>	<b>Session 2   Cell-of-origin, differentiation, subtype</b>
<i>Session chairs</i>	<i>Patrick Michl (University Medicine Halle, DE)</i> <i>Max Reichert (University Hospital rechts der Isar, Technical University of Munich, DE)</i>
9:00–9:30 am	Laura D. Wood (Johns Hopkins School of Medicine, Baltimore, US) Precancerous pancreatic neoplasms: the serpent's egg
9:30–10:00 am	Francisco Real (Spanish National Cancer Research Centre (CNIO), Madrid, ES) Gut microbiome depletion rescues the pre-inflammatory phenotype resulting from Nr5a2 haploinsufficiency
10:00–10:30 am	Ilse Rooman (Vrije Universiteit Brussel, BE) Pancreatic cancer origin and plasticity, a "masked ball" of exocrine cells
10:30–11:00 am	Break
11:00–11:30 am	Axel Behrens (CRUK Convergence Science Centre, Institute of Cancer Research & Imperial College London, GB) Molecular mechanisms controlling cellular heterogeneity of pancreatic cancer
11:30–12:00 am	Peter Bailey (Department of General Surgery, Heidelberg University Hospital, Heidelberg, DE; Institute of Cancer Sciences, Glasgow, GB) Intratumor heterogeneity and drug tolerance in PDA
12:00–12:15 am	Short talk Helmut Laumen (Research Training Group 2751 InCuPanC, University Halle, DE) CPA1-induced inflammation modulates pancreatic carcinogenesis
<b>12:30 am–1:30 pm</b>	<b>Lunch break</b>
<b>1:30–3:00 pm</b>	<b>Session 3, Part 1   Tumor microenvironment</b>
<i>Session chairs</i>	<i>Matthias Lauth (Philipps-University Marburg, DE)</i> <i>Christoph Michalski (University Hospital Ulm, DE)</i>
1:30–2:00 pm	Melanie Börries (Molecular Medicine and Cell Research, University of Freiburg, DE) The impact of the tumor microenvironment in pancreatic cancer
2:00–2:30 pm	Marina Pasca di Magliano (University of Michigan Medical School, Ann Arbor, US) Dissecting T cell responses in human and mouse pancreatic cancer
2:30–3:00 pm	Jen Morton (The Beatson Institute for Cancer Research, Glasgow, GB) Targeting immune cells in mouse models of pancreatic cancer
<b>3:00–5:00 pm</b>	<b>Break</b>
<b>5:00–6:15 pm</b>	<b>Session 3, Part 2   Tumor microenvironment</b>
5:00–5:30 pm	Raghu Kalluri (The University of Texas MD Anderson Cancer Center, US) Tumor microenvironment functionally controls the progression of pancreatic cancer
5:30–6:00 pm	Robert Schwabe (Columbia University Medical Center, New York, US) The role of hepatic stellate cells and type I collagen in pancreatic cancer liver metastasis
6:00–6:15 pm	Short talk Veronika Lutz (Clinical Research Unit 325, Institute for Medical Microbiology and Hospital Hygiene, Philipps-University Marburg, DE) IL-17-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts

**Wednesday, 1 June 2022**

<b>9:00–10:45 pm</b>	<b>Session 4   Genome Dynamics</b>
<i>Session Chairs</i>	<i>Volker Ellenrieder (University Medical Center Göttingen, DE)</i> <i>Günter Schneider (University Medical Center Göttingen, DE)</i>
9:00–9:30 am	Elisabeth Heßmann (University Medical Center Göttingen, DE) Interplay between ARID1A deficiency and inflammatory signaling in pancreatic plasticity and cancer
9:30–10:00 am	Matthias Hebrok (Diabetes Center at the University of California (UCSF), US) Epigenetic regulators of pancreatic cancer
10:00–10:30 am	Gioacchino Natoli (European Institute of Oncology (IEO), Milano, IT) Coexisting biotypes in PDAC
10:30–10:45 am	Short talk Laura Urbach (Clinical Research Unit 5002, Department of Gastroenterology, Gastrointestinal Oncology & Endocrinology, University Medical Center Göttingen, DE) Gain-of-function p53 mutants in pancreatic cancer subtype specification
10:45–11:15 am	Break
<b>11:15–1:00 pm</b>	<b>Session 5   Emerging therapeutic concepts</b>
<i>Session chairs</i>	<i>Julia Mayerle (Hospital of the Ludwig-Maximilians University Munich, DE)</i> <i>Thomas T. W. Seufferlein (University Hospital Ulm, DE)</i>
11:15–11:45 am	Diane Simeone (NYU Langone Health, New York, US) A new paradigm in clinical trial design in pancreatic cancer: precision promise
11:45–12:15 am	Eric Collisson (University of California, San Francisco, US) Ferroaddiction in pancreatic ductal adenocarcinoma
12:15–12:45 am	Matthias Wirth (Charité – Universitätsmedizin Berlin, DE) NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
12:45–1:00 pm	Short talk PI3K signaling mediated whole genome doubling drives pancreatic cancer progression and defines subtype specific therapeutic vulnerabilities Chiara Falcomatà (CRC1321, Institute of Translational Cancer Research and Experimental Cancer Therapy, TranslaTUM, Technical University of Munich, DE)
<b>1:00 pm</b>	<b>Closing remarks</b>